Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is Manager of Event & Health Communications, working on communications for BIO’s events and health care policy issues. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He is currently finishing up a Master’s degree in communications at Georgetown University.

Latest Posts

WSJ Editorial: The Medical Innovation Threat

???????????????????????????????

An editorial in today’s Wall Street Journal looks at the rising threat the American insurance industry’s increasingly loud attacks on Sovaldi, a revolutionary new Hepatitis C treatment pose for medical innovation and the development of new specialty drugs. As the editors rightly note, “Sovaldi is the kind of medicine that the drug scolds claim to want—a true scientific advance with a near-perfect cure rate for Hepatitis C, the liver-destroying virus that infects one of every 100 Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

National Immunization Awareness Month

Vaccination

August is National Immunization Awareness Month, providing a reminder of the importance of proper vaccination just as kids are heading back to school. Schools are a prime venue for transmitting vaccine-preventable diseases, and school-age children can further spread disease to their families and others with whom they come in contact. As children get older, they are at an increased risk for some infections, and the protection from some childhood vaccines begins to fade, requiring a Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

Seattle Times Commentary: New Approaches Needed to Fight Ebola

scientist-eyedropper

In the Seattle Times this week, BIO Ventures for Global Health President Jennifer Dent offered commentary on the need for new drug development models to develop treatments for Ebola, arguing that conventional approaches are not working for neglected tropical diseases. Partnerships involving drug companies as well as academic, non-profit, and government stakeholders are needed. Dent offers the WIPO Re:Search consortium as an example: In 2011, BIO Ventures for Global Health established a partnership with the Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Presents at 2014 Biological Weapons Convention Meeting of Experts

Palais des nations

Last week marked the annual Biological Weapons Convention (BWC) Meeting of Experts in Geneva. The BWC is a multi-national treaty prohibiting the manufacture of biological weapons, and also contains provisions related to national implementation and multi-national coordination for preparedness and assistance. Each year a Meeting of Experts takes place to discuss ongoing issues related to the implementation of the treaty. This year, for the first time ever, BIO was invited to present on novel technologies Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Forbes: Faster FDA Approvals Have Not Caused More Drug Safety Problems

FDA115x76

In 1992, Congress, industry, and the FDA worked together to create the Prescription Drug User Fee Act (PDUFA). This program ensures that FDA has the ability to hire additional reviewers to expedite the drug review process by having industry pay “user fees.” Recently, attention has been given to a flawed study in the August 2014 issue of Health Affairs, which has some critics claiming that PDUFA fees are biasing FDA review decisions. The study looked at Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,